These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 14978067)
1. Dendritic cell activation kinetics and cancer immunotherapy. Bellone M; Camporeale A; Boni A J Immunol; 2004 Mar; 172(5):2727-8. PubMed ID: 14978067 [No Abstract] [Full Text] [Related]
2. Dendritic cells in cancer immunotherapy. 10 January 2005, London, UK. George AJ IDrugs; 2005 Feb; 8(2):104-6. PubMed ID: 15696407 [No Abstract] [Full Text] [Related]
3. Dendritic cells and immunotherapy for malignant disease. Reid DC Br J Haematol; 2001 Mar; 112(4):874-87. PubMed ID: 11298582 [No Abstract] [Full Text] [Related]
4. Why are dendritic cells central to cancer immunotherapy? Colaco CA Mol Med Today; 1999 Jan; 5(1):14-7. PubMed ID: 10088127 [TBL] [Abstract][Full Text] [Related]
5. [Significance of dendritic cells for the immunotherapy of tumors]. Weise JB; Maune S; Kabelitz D; Heiser A HNO; 2005 Feb; 53(2):117-20. PubMed ID: 15657753 [No Abstract] [Full Text] [Related]
6. Novel perspectives on dendritic cell-based immunotherapy of cancer. Bonaccorsi I; Pezzino G; Morandi B; Ferlazzo G Immunol Lett; 2013; 155(1-2):6-10. PubMed ID: 24076312 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cells: a journey from laboratory to clinic. Cerundolo V; Hermans IF; Salio M Nat Immunol; 2004 Jan; 5(1):7-10. PubMed ID: 14699398 [No Abstract] [Full Text] [Related]
12. Science, medicine, and the future: Cellular immunotherapy for cancer. Armstrong AC; Eaton D; Ewing JC BMJ; 2001 Dec; 323(7324):1289-93. PubMed ID: 11731394 [No Abstract] [Full Text] [Related]
13. Dendritic cells as vectors for therapy. Banchereau J; Schuler-Thurner B; Palucka AK; Schuler G Cell; 2001 Aug; 106(3):271-4. PubMed ID: 11509176 [No Abstract] [Full Text] [Related]
14. Immunotherapy with dendritic cells for cancer. Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615 [TBL] [Abstract][Full Text] [Related]
15. Cellular immunotherapy of cancer: an overview and future directions. Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516 [TBL] [Abstract][Full Text] [Related]
16. Current status and future applications of cellular therapies for cancer. Copier J; Bodman-Smith M; Dalgleish A Immunotherapy; 2011 Apr; 3(4):507-16. PubMed ID: 21463192 [TBL] [Abstract][Full Text] [Related]
17. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Cho NH; Cheong TC; Min JH; Wu JH; Lee SJ; Kim D; Yang JS; Kim S; Kim YK; Seong SY Nat Nanotechnol; 2011 Sep; 6(10):675-82. PubMed ID: 21909083 [TBL] [Abstract][Full Text] [Related]
18. Bone marrow-derived IFN-producing killer dendritic cells account for the tumoricidal activity of unpulsed dendritic cells. Himoudi N; Nabarro S; Buddle J; Eddaoudi A; Thrasher AJ; Anderson J J Immunol; 2008 Nov; 181(9):6654-63. PubMed ID: 18941256 [TBL] [Abstract][Full Text] [Related]
19. In vitro priming to tumor-associated proteins. Hand SL; Bernhard H; Huseby ES; Rubin WD; Disis ML; Cheever MA Adv Exp Med Biol; 1997; 417():503-9. PubMed ID: 9286411 [No Abstract] [Full Text] [Related]
20. A review of dendritic cell therapy for cancer: progress and challenges. Mantia-Smaldone GM; Chu CS BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]